Description: Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.
Home Page: aadibio.com
AADI Technical Analysis
17383 Sunset Boulevard
Pacific Palisades,
CA
90272
United States
Phone:
424 473 8055
Officers
| Name | Title |
|---|---|
| Dr. Neil P. Desai Ph.D. | Founder, Pres, CEO, Sec. & Director |
| Mr. Scott M. Giacobello CPA | CFO & Treasurer |
| Mr. Brendan P. Delaney M.B.A. | Chief Operating Officer |
| Ms. Marcy Graham | SVP of Investor Relations & Corp. Communications |
| Mr. Stephen M. Rodin J.D. | Sr. VP of Legal & Gen. Counsel |
| Mr. Raymond G. Steitz | Sr. VP of HR & Chief HR Officer |
| Dr. Loretta M. Itri F.A.C.P., M.D. | Chief Medical Officer |
| Mr. Bryan Ball | Chief Quality Officer & Sr. VP of Manufacturing Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.5859 |
| Price-to-Book MRQ: | 1.8927 |
| Price-to-Sales TTM: | 28.1934 |
| IPO Date: | 2017-08-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 76 |